| . | All (N = 2128) . | OCT guidance (n = 1056) . | Angiography guidance (n = 1072) . | P-value . |
|---|---|---|---|---|
| Age, years | 65.3 ± 10.4 | 65.2 ± 10.5 | 65.4 ± 10.4 | .68 |
| Male sex | 1637 (76.9) | 827 (78.3) | 810 (75.6) | .13 |
| Racea | ||||
| White | 1292/1643 (78.6) | 648/819 (79.1) | 644/824 (78.2) | .63 |
| Black | 67/1643 (4.1) | 32/819 (3.9) | 35/824 (4.2) | .73 |
| Asian | 268/1643 (16.3) | 133/819 (16.2) | 135/824 (16.4) | .94 |
| Other | 16/1643 (1.0) | 6/819 (0.7) | 10/824 (1.2) | .32 |
| Hispanic or Latino ethnic groupa | 111/1597 (7.0) | 53/797 (6.6) | 58/800 (7.3) | .64 |
| Hypertension | 1527 (71.8) | 743 (70.4) | 784 (73.1) | .16 |
| Dyslipidaemia | 1411 (66.3) | 684 (64.8) | 727 (67.8) | .14 |
| Diabetes mellitus | 876 (41.2) | 440 (41.7) | 436 (40.7) | .64 |
| Treated with any medication | 834 (39.2) | 416 (39.4) | 418 (39.0) | .85 |
| Treated with insulin | 261 (12.3) | 123 (11.6) | 138 (12.9) | .39 |
| Current smoker | 427/2127 (20.1) | 211 (20.0) | 216/1071 (20.2) | .91 |
| Body mass index, kg/m2 | 28.7 ± 5.3 | 28.6 ± 5.1 | 28.8 ± 5.4 | .38 |
| Previous myocardial infarction | 472 (22.2) | 216 (20.5) | 256 (23.9) | .06 |
| Previous PCI in the target vessel | 269/2095 (12.8) | 134/1035 (12.9) | 135/1060 (12.7) | .89 |
| Previous coronary artery bypass grafting | 90 (4.2) | 49 (4.6) | 41 (3.8) | .35 |
| Serum creatinine level, mg/dLb | 0.95 ± 0.23 | 0.95 ± 0.23 | 0.96 ± 0.24 | .62 |
| Creatinine clearance, mL/min/1.73 m2b,c | 79.2 ± 21.2 | 79.7 ± 21.1 | 78.8 ± 21.2 | .37 |
| <60 mL/min/1.73 m2 | 353/2067 (17.1) | 161/1025 (15.7) | 192/1042 (18.4) | .10 |
| Dialysis | 46 (2.2) | 23 (2.2) | 23 (2.1) | .96 |
| Left ventricular ejection fraction, % | 55.3 ± 8.6 | 55.2 ± 8.5 | 55.3 ± 8.6 | .79 |
| Clinical presentation | ||||
| Silent ischaemia | 313 (14.7) | 145 (13.7) | 168 (15.7) | .21 |
| Stable angina | 610 (28.7) | 296 (28.0) | 314 (29.3) | .52 |
| Unstable angina | 579 (27.2) | 291 (27.6) | 288 (26.9) | .72 |
| Non-STEMI | 504 (23.7) | 265 (25.1) | 239 (22.3) | .13 |
| Recent STEMId | 122 (5.7) | 59 (5.6) | 63 (5.9) | .77 |
| Outpatient pharmacologic therapy | ||||
| Any antiplatelet therapy | 1685 (79.2) | 827 (78.3) | 858 (80.0) | .33 |
| Aspirin | 1612 (75.8) | 782 (74.1) | 830 (77.4) | .07 |
| P2Y12 antagonist | 1065 (50.0) | 534 (50.6) | 531 (49.5) | .63 |
| Dual antiplatelet therapy | 992 (46.6) | 489 (46.3) | 503 (46.9) | .78 |
| Beta-blocker | 1148 (53.9) | 585 (55.4) | 563 (52.5) | .18 |
| Calcium-channel blocker | 467 (21.9) | 232 (22.0) | 235 (21.9) | .98 |
| ACE inhibitor or ARB | 1190 (55.9) | 598 (56.6) | 592 (55.2) | .51 |
| Statin | 1506 (70.8) | 744 (70.5) | 762 (71.1) | .75 |
| Long-term oral anticoagulant | 157 (7.4) | 87 (8.2) | 70 (6.5) | .13 |
| Vitamin K antagonist | 24 (1.1) | 14 (1.3) | 10 (0.9) | .39 |
| Direct-acting oral anticoagulant | 133 (6.3) | 73 (6.9) | 60 (5.6) | .21 |
| . | All (N = 2128) . | OCT guidance (n = 1056) . | Angiography guidance (n = 1072) . | P-value . |
|---|---|---|---|---|
| Age, years | 65.3 ± 10.4 | 65.2 ± 10.5 | 65.4 ± 10.4 | .68 |
| Male sex | 1637 (76.9) | 827 (78.3) | 810 (75.6) | .13 |
| Racea | ||||
| White | 1292/1643 (78.6) | 648/819 (79.1) | 644/824 (78.2) | .63 |
| Black | 67/1643 (4.1) | 32/819 (3.9) | 35/824 (4.2) | .73 |
| Asian | 268/1643 (16.3) | 133/819 (16.2) | 135/824 (16.4) | .94 |
| Other | 16/1643 (1.0) | 6/819 (0.7) | 10/824 (1.2) | .32 |
| Hispanic or Latino ethnic groupa | 111/1597 (7.0) | 53/797 (6.6) | 58/800 (7.3) | .64 |
| Hypertension | 1527 (71.8) | 743 (70.4) | 784 (73.1) | .16 |
| Dyslipidaemia | 1411 (66.3) | 684 (64.8) | 727 (67.8) | .14 |
| Diabetes mellitus | 876 (41.2) | 440 (41.7) | 436 (40.7) | .64 |
| Treated with any medication | 834 (39.2) | 416 (39.4) | 418 (39.0) | .85 |
| Treated with insulin | 261 (12.3) | 123 (11.6) | 138 (12.9) | .39 |
| Current smoker | 427/2127 (20.1) | 211 (20.0) | 216/1071 (20.2) | .91 |
| Body mass index, kg/m2 | 28.7 ± 5.3 | 28.6 ± 5.1 | 28.8 ± 5.4 | .38 |
| Previous myocardial infarction | 472 (22.2) | 216 (20.5) | 256 (23.9) | .06 |
| Previous PCI in the target vessel | 269/2095 (12.8) | 134/1035 (12.9) | 135/1060 (12.7) | .89 |
| Previous coronary artery bypass grafting | 90 (4.2) | 49 (4.6) | 41 (3.8) | .35 |
| Serum creatinine level, mg/dLb | 0.95 ± 0.23 | 0.95 ± 0.23 | 0.96 ± 0.24 | .62 |
| Creatinine clearance, mL/min/1.73 m2b,c | 79.2 ± 21.2 | 79.7 ± 21.1 | 78.8 ± 21.2 | .37 |
| <60 mL/min/1.73 m2 | 353/2067 (17.1) | 161/1025 (15.7) | 192/1042 (18.4) | .10 |
| Dialysis | 46 (2.2) | 23 (2.2) | 23 (2.1) | .96 |
| Left ventricular ejection fraction, % | 55.3 ± 8.6 | 55.2 ± 8.5 | 55.3 ± 8.6 | .79 |
| Clinical presentation | ||||
| Silent ischaemia | 313 (14.7) | 145 (13.7) | 168 (15.7) | .21 |
| Stable angina | 610 (28.7) | 296 (28.0) | 314 (29.3) | .52 |
| Unstable angina | 579 (27.2) | 291 (27.6) | 288 (26.9) | .72 |
| Non-STEMI | 504 (23.7) | 265 (25.1) | 239 (22.3) | .13 |
| Recent STEMId | 122 (5.7) | 59 (5.6) | 63 (5.9) | .77 |
| Outpatient pharmacologic therapy | ||||
| Any antiplatelet therapy | 1685 (79.2) | 827 (78.3) | 858 (80.0) | .33 |
| Aspirin | 1612 (75.8) | 782 (74.1) | 830 (77.4) | .07 |
| P2Y12 antagonist | 1065 (50.0) | 534 (50.6) | 531 (49.5) | .63 |
| Dual antiplatelet therapy | 992 (46.6) | 489 (46.3) | 503 (46.9) | .78 |
| Beta-blocker | 1148 (53.9) | 585 (55.4) | 563 (52.5) | .18 |
| Calcium-channel blocker | 467 (21.9) | 232 (22.0) | 235 (21.9) | .98 |
| ACE inhibitor or ARB | 1190 (55.9) | 598 (56.6) | 592 (55.2) | .51 |
| Statin | 1506 (70.8) | 744 (70.5) | 762 (71.1) | .75 |
| Long-term oral anticoagulant | 157 (7.4) | 87 (8.2) | 70 (6.5) | .13 |
| Vitamin K antagonist | 24 (1.1) | 14 (1.3) | 10 (0.9) | .39 |
| Direct-acting oral anticoagulant | 133 (6.3) | 73 (6.9) | 60 (5.6) | .21 |
Data are presented as means ± SD or n (%) or n/total n (%).
ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; CABG, coronary bypass grafting; OCT, optical coherence tomography; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.
aData on race or ethnicity are missing from patients who declined to answer or were precluded from disclosing due to local regulations.
bExcluding patients on dialysis.
cEstimated using modification of diet in renal disease equation.
dRecent STEMI was defined as STEMI that had occurred within the previous 24 h.
| . | All (N = 2128) . | OCT guidance (n = 1056) . | Angiography guidance (n = 1072) . | P-value . |
|---|---|---|---|---|
| Age, years | 65.3 ± 10.4 | 65.2 ± 10.5 | 65.4 ± 10.4 | .68 |
| Male sex | 1637 (76.9) | 827 (78.3) | 810 (75.6) | .13 |
| Racea | ||||
| White | 1292/1643 (78.6) | 648/819 (79.1) | 644/824 (78.2) | .63 |
| Black | 67/1643 (4.1) | 32/819 (3.9) | 35/824 (4.2) | .73 |
| Asian | 268/1643 (16.3) | 133/819 (16.2) | 135/824 (16.4) | .94 |
| Other | 16/1643 (1.0) | 6/819 (0.7) | 10/824 (1.2) | .32 |
| Hispanic or Latino ethnic groupa | 111/1597 (7.0) | 53/797 (6.6) | 58/800 (7.3) | .64 |
| Hypertension | 1527 (71.8) | 743 (70.4) | 784 (73.1) | .16 |
| Dyslipidaemia | 1411 (66.3) | 684 (64.8) | 727 (67.8) | .14 |
| Diabetes mellitus | 876 (41.2) | 440 (41.7) | 436 (40.7) | .64 |
| Treated with any medication | 834 (39.2) | 416 (39.4) | 418 (39.0) | .85 |
| Treated with insulin | 261 (12.3) | 123 (11.6) | 138 (12.9) | .39 |
| Current smoker | 427/2127 (20.1) | 211 (20.0) | 216/1071 (20.2) | .91 |
| Body mass index, kg/m2 | 28.7 ± 5.3 | 28.6 ± 5.1 | 28.8 ± 5.4 | .38 |
| Previous myocardial infarction | 472 (22.2) | 216 (20.5) | 256 (23.9) | .06 |
| Previous PCI in the target vessel | 269/2095 (12.8) | 134/1035 (12.9) | 135/1060 (12.7) | .89 |
| Previous coronary artery bypass grafting | 90 (4.2) | 49 (4.6) | 41 (3.8) | .35 |
| Serum creatinine level, mg/dLb | 0.95 ± 0.23 | 0.95 ± 0.23 | 0.96 ± 0.24 | .62 |
| Creatinine clearance, mL/min/1.73 m2b,c | 79.2 ± 21.2 | 79.7 ± 21.1 | 78.8 ± 21.2 | .37 |
| <60 mL/min/1.73 m2 | 353/2067 (17.1) | 161/1025 (15.7) | 192/1042 (18.4) | .10 |
| Dialysis | 46 (2.2) | 23 (2.2) | 23 (2.1) | .96 |
| Left ventricular ejection fraction, % | 55.3 ± 8.6 | 55.2 ± 8.5 | 55.3 ± 8.6 | .79 |
| Clinical presentation | ||||
| Silent ischaemia | 313 (14.7) | 145 (13.7) | 168 (15.7) | .21 |
| Stable angina | 610 (28.7) | 296 (28.0) | 314 (29.3) | .52 |
| Unstable angina | 579 (27.2) | 291 (27.6) | 288 (26.9) | .72 |
| Non-STEMI | 504 (23.7) | 265 (25.1) | 239 (22.3) | .13 |
| Recent STEMId | 122 (5.7) | 59 (5.6) | 63 (5.9) | .77 |
| Outpatient pharmacologic therapy | ||||
| Any antiplatelet therapy | 1685 (79.2) | 827 (78.3) | 858 (80.0) | .33 |
| Aspirin | 1612 (75.8) | 782 (74.1) | 830 (77.4) | .07 |
| P2Y12 antagonist | 1065 (50.0) | 534 (50.6) | 531 (49.5) | .63 |
| Dual antiplatelet therapy | 992 (46.6) | 489 (46.3) | 503 (46.9) | .78 |
| Beta-blocker | 1148 (53.9) | 585 (55.4) | 563 (52.5) | .18 |
| Calcium-channel blocker | 467 (21.9) | 232 (22.0) | 235 (21.9) | .98 |
| ACE inhibitor or ARB | 1190 (55.9) | 598 (56.6) | 592 (55.2) | .51 |
| Statin | 1506 (70.8) | 744 (70.5) | 762 (71.1) | .75 |
| Long-term oral anticoagulant | 157 (7.4) | 87 (8.2) | 70 (6.5) | .13 |
| Vitamin K antagonist | 24 (1.1) | 14 (1.3) | 10 (0.9) | .39 |
| Direct-acting oral anticoagulant | 133 (6.3) | 73 (6.9) | 60 (5.6) | .21 |
| . | All (N = 2128) . | OCT guidance (n = 1056) . | Angiography guidance (n = 1072) . | P-value . |
|---|---|---|---|---|
| Age, years | 65.3 ± 10.4 | 65.2 ± 10.5 | 65.4 ± 10.4 | .68 |
| Male sex | 1637 (76.9) | 827 (78.3) | 810 (75.6) | .13 |
| Racea | ||||
| White | 1292/1643 (78.6) | 648/819 (79.1) | 644/824 (78.2) | .63 |
| Black | 67/1643 (4.1) | 32/819 (3.9) | 35/824 (4.2) | .73 |
| Asian | 268/1643 (16.3) | 133/819 (16.2) | 135/824 (16.4) | .94 |
| Other | 16/1643 (1.0) | 6/819 (0.7) | 10/824 (1.2) | .32 |
| Hispanic or Latino ethnic groupa | 111/1597 (7.0) | 53/797 (6.6) | 58/800 (7.3) | .64 |
| Hypertension | 1527 (71.8) | 743 (70.4) | 784 (73.1) | .16 |
| Dyslipidaemia | 1411 (66.3) | 684 (64.8) | 727 (67.8) | .14 |
| Diabetes mellitus | 876 (41.2) | 440 (41.7) | 436 (40.7) | .64 |
| Treated with any medication | 834 (39.2) | 416 (39.4) | 418 (39.0) | .85 |
| Treated with insulin | 261 (12.3) | 123 (11.6) | 138 (12.9) | .39 |
| Current smoker | 427/2127 (20.1) | 211 (20.0) | 216/1071 (20.2) | .91 |
| Body mass index, kg/m2 | 28.7 ± 5.3 | 28.6 ± 5.1 | 28.8 ± 5.4 | .38 |
| Previous myocardial infarction | 472 (22.2) | 216 (20.5) | 256 (23.9) | .06 |
| Previous PCI in the target vessel | 269/2095 (12.8) | 134/1035 (12.9) | 135/1060 (12.7) | .89 |
| Previous coronary artery bypass grafting | 90 (4.2) | 49 (4.6) | 41 (3.8) | .35 |
| Serum creatinine level, mg/dLb | 0.95 ± 0.23 | 0.95 ± 0.23 | 0.96 ± 0.24 | .62 |
| Creatinine clearance, mL/min/1.73 m2b,c | 79.2 ± 21.2 | 79.7 ± 21.1 | 78.8 ± 21.2 | .37 |
| <60 mL/min/1.73 m2 | 353/2067 (17.1) | 161/1025 (15.7) | 192/1042 (18.4) | .10 |
| Dialysis | 46 (2.2) | 23 (2.2) | 23 (2.1) | .96 |
| Left ventricular ejection fraction, % | 55.3 ± 8.6 | 55.2 ± 8.5 | 55.3 ± 8.6 | .79 |
| Clinical presentation | ||||
| Silent ischaemia | 313 (14.7) | 145 (13.7) | 168 (15.7) | .21 |
| Stable angina | 610 (28.7) | 296 (28.0) | 314 (29.3) | .52 |
| Unstable angina | 579 (27.2) | 291 (27.6) | 288 (26.9) | .72 |
| Non-STEMI | 504 (23.7) | 265 (25.1) | 239 (22.3) | .13 |
| Recent STEMId | 122 (5.7) | 59 (5.6) | 63 (5.9) | .77 |
| Outpatient pharmacologic therapy | ||||
| Any antiplatelet therapy | 1685 (79.2) | 827 (78.3) | 858 (80.0) | .33 |
| Aspirin | 1612 (75.8) | 782 (74.1) | 830 (77.4) | .07 |
| P2Y12 antagonist | 1065 (50.0) | 534 (50.6) | 531 (49.5) | .63 |
| Dual antiplatelet therapy | 992 (46.6) | 489 (46.3) | 503 (46.9) | .78 |
| Beta-blocker | 1148 (53.9) | 585 (55.4) | 563 (52.5) | .18 |
| Calcium-channel blocker | 467 (21.9) | 232 (22.0) | 235 (21.9) | .98 |
| ACE inhibitor or ARB | 1190 (55.9) | 598 (56.6) | 592 (55.2) | .51 |
| Statin | 1506 (70.8) | 744 (70.5) | 762 (71.1) | .75 |
| Long-term oral anticoagulant | 157 (7.4) | 87 (8.2) | 70 (6.5) | .13 |
| Vitamin K antagonist | 24 (1.1) | 14 (1.3) | 10 (0.9) | .39 |
| Direct-acting oral anticoagulant | 133 (6.3) | 73 (6.9) | 60 (5.6) | .21 |
Data are presented as means ± SD or n (%) or n/total n (%).
ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; CABG, coronary bypass grafting; OCT, optical coherence tomography; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.
aData on race or ethnicity are missing from patients who declined to answer or were precluded from disclosing due to local regulations.
bExcluding patients on dialysis.
cEstimated using modification of diet in renal disease equation.
dRecent STEMI was defined as STEMI that had occurred within the previous 24 h.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
